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 ABSTRACT 
We synthesized new indolylarylsulfone (IAS) derivatives carrying a heterocyclic tail at the indole-2-
carboxamide nitrogen as potential anti-HIV/AIDS agents. Several new IASs yielded EC50 values <1.0 
nM against the HIV-1 WT and mutant strains in MT-4 cells. The enantiomer (R)-11 proved to be 
exceptionally potent against the whole viral panel; in the RT screening assay it was remarkably 
superior to NVP and EFV and comparable to ETV. The binding poses were consistent with the one 
previously described for the IAS NNRTIs. Docking studies showed that the methyl group of the (R)-11 
pointed towards the cleft created by the K103N mutation, differently from the corresponding group of 
(S)-11. By calculating the solvent accessible surface, we observed that the exposed area of the RT in 
complex with (S)-11 was larger than the area of the (R)-11 complex. Compounds 6 and 16 and the 
enantiomer (R)-11 represent novel robust lead compounds of the IAS class. 
 
  
INTRODUCTION 
Human immunodeficiency virus type 1 (HIV-1) infection and acquired immunodeficiency syndrome 
(AIDS) are clinically treated with antiretroviral agents,1 as the development of an effective HIV-1 
vaccine still remains problematic.2 Antiretroviral drugs used in the treatment of HIV infection may be 
viewed as falling into nucleoside reverse transcriptase inhibitors (NRTIs) that also include the 
nucleotide agents, no nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), 
fusion inhibitors (FIs), entry inhibitors - CCR5 co-receptor antagonists, and HIV integrase strand 
transfer inhibitors (INSTIs).  Such antiretroviral agents are administered singly or combined into multi-
drug combination products.3,4 
The clinical treatment for HIV/AIDS takes advantage of the multiple benefits of the antiretroviral 
therapy (ART), also known as active antiretroviral therapy (HAART). ART abides of two or at least 
three antiretroviral drugs from different drug classes. The life-saving ART regimens suppress the HIV-
1 replication and slow down the progression of viral infection, particularly in early stages of the disease, 
maintaining plasma viremia below the detection level in most patients undergoing treatment for at least 
six months.5 
Nevirapine (NVP), Delavirdine (DLV) and Efavirenz (EFV) are first-generation NNRTIs; it is 
recognized that such agents rapidly develop drug resistance; in particular the K103N and Y181C 
mutations are prevalent from clinical HIV-1 isolates.6 Newer NNRTIs, Etravirine (ETV) and 
Rilpivirine (RPV) were approved for use in drug combination to manage treatment-experienced HIV-1 
infected people, and naïve and adult patients, respectively.7 However, despite a significant progress, 
drug resistance and adverse effects continue to emerge in ART receiving patients.8 These data 
underlines the need of new antiretroviral agents with improved and tolerability resistance profiles. 
 
 
Chart 1. Structure of New IASs 4-20 and Reference 
Compounds 1-3.a 
 
 
a4-20: R1 = H; cyclic group = phenyl, pyridinyl, pyrimidinyl, 
heterocyclyl; linker = 0, CH2, CH2CH2, CHMe, NH, NMe; R2 = 
3,5-Me2, 2,6-Me2, 2,6-Cl2 (see Table 1). 
 
 
In the indolylarylsulfone (IAS) HIV-1 NNRTI class, the two methyl groups at positions 3’ and 5’ of 
the 3-phenylsulfonyl moiety proved to ensure a broad spectrum of activity against mutant HIV-1 strains. 
The indole-2-carboxamide demonstrated to tolerate a wide diversity of substituents (natural or 
unnatural amino acids, hydroxyethyl moiety, Mannich bases) to provide IAS analogues with 
remarkable antiviral potency.9 
The introduction of an additional aromatic nucleus to the parent compound resulted in NNRTIs with 
broad spectrum of activity against the mutant HIV-1 strains.10 Accordingly, IAS derivatives bearing an 
additional (third) cyclic moiety linked through 1C or 2C spacer group the 2-carboxamide nitrogen (1-3) 
showed potent antiretroviral activity.11,12 Therefore, we planned the synthesis of new inhibitors that 
would address this drug design strategy. The new IAS derivatives 4-20 showed potent HIV-1 inhibitory 
activity in the low nanomolar range (Chart 1 and Table 1). 
Scheme 1. Synthesis of Carboxamides 4-20.a 
 
aReagents and reaction conditions: (a) amine, BOP reagent, triethylamine, anhydrous DMF, 
25 °C, 12 h, yield (%) 40-82; (b) 30% NH4OH, EtOH, 60 °C, overnight, yield (%) 32-35. 
 
 
 
CHEMISTRY 
Carboxamides 4-6 and 9-20 were synthesized by coupling reaction of the indole acids 21,9a 22 and 23 
with the appropriate amine in the presence of (benzotriazol-1-yloxy)tris(dimethylamino)-phosphonium 
hexafluorophosphate (BOP reagent) and triethylamine in anhydrous DMF at 25 °C for 12 h. On the 
other hand, esters 29 and 30 were transformed into the corresponding carboxamides 7 and 8 by heating 
at 60 °C with 30% ammonium hydroxide in ethanol (Scheme 1). 
  
Scheme 2. Synthesis of Intermediates 22 and 23.a 
 
 
aReagents and reaction conditions: a) (a) (i) NaH, anhydrous DMF, 25 °C, 10 min; (ii) DADS 
110 °C, 12 h, (b) thionyl chloride, anhydrous EtOH, reflux, 12 h, yield (%) 51-62; (c) MCPBA, 
CHCl3, 25 °C, 2 h, yield (%) 67-75; (d) LiOH, THF/H2O, 25 °C, 48 h, yield (%) 85-96; b) (e) 
1,3-dibromo-5,5-dimethylhydantoin, CHCl3, 25 °C, 5 min, yield (%) 91-99. 
 
 
The starting acids 22 and 23 were obtained by reaction of the proper diaryldisulfides (DADS) 33 or 
34 with ethyl 5-chloro-1H-indole-2-carboxylic acid (24) in the presence of sodium hydride according 
to the Atkinson reaction13 to provide the corresponding 3-arylthio-1H-indole-2-carboxylic acids 25 or 
26. Esterification was achieved by treating of 25, 26 with thionyl chloride in anhydrous ethanol at 
80 °C overnight to furnish the intermediates 27 or 28 (Scheme 2, panel a). 
 
  
Figure 1. HPLC enantioseparation of 11 (panel A). Column Chiralcel OD 250 mm × 4.6 mm I.D.; detection, UV at 280 nm; 
mobile phase, n-hexane-ethanol 1:1 (v/v); flow rate, 1.0 mL min−1; column temp. 25 °C. Comparison of the CD spectra of 
the enantiomers (S)-11 and (R)-11 (panel B) with those of (R)-3 and (S)-3 (panel C) recorded in ethanol at 20 °C. 
  
 
Oxidation of 27 and 28 to the corresponding sulfones 29 and 30 was performed with 3-
chloroperoxybenzoic acid (MCPBA) in chloroform at room temperature. Lithium hydroxide hydrolysis 
of the esters 29 and 30 afforded the required acids 22 and 23, respectively. The DADSs 33 and 34 were 
prepared by oxidation of proper thiophenols in the presence of 1,3-dibromo-5,5-dimethylhydantoin 
(Scheme 2, panel b). 
Direct enantioseparation of the racemic mixture (R,S)-11 was performed by enantioselective HPLC 
using the cellulose derived Chiralcel OD chiral stationary phase (CSP) and the binary mixture n-
hexane-ethanol 50:50 as a mobile phase (Figure 1A). The optimized analytical enantioselective method 
was scaled-up to a semi-preparative level to obtain mg-amounts of the pure enantiomers for the 
screening. The stereochemical characterization of (S)-11 and (R)-11 was performed by circular 
dichroism (CD) correlation method using the (R)-3 and (S)-3 pure enantiomers as reference samples 
(Figure 1B and 1C). The (R) configuration was empirically assigned to the more retained enantiomer  
(S)-11 on the Chiralcel OD CSP, and the (S) configuration to the less retained enantiomer (R)-11. 
 
RESULTS AND DISCUSSION 
Independently on the substituent at the nitrogen atom at the position 2 of the indole, a large proportion 
of the new IASs inhibited the HIV-1 NL4-3 strain by fifty-percent (EC50 values) in the sub-nanomolar 
range of concentrations (MTT method). Compounds 4, 5, 6, 8, 12, 13, 17, 18 and 20, were highly 
inhibitory to the HIV-1 replication at the lowest detectable nM concentration (Table 1). The majority of 
the new IASs were superior to the reference drugs NVP, EFV, and AZT. Unless 8, the new IAS 
derivatives showed cytotoxic concentrations (EC50 values) >20000 nM. With the exception of 7, 9 and 
14, the new derivatives showed selectivity indexes (SI = CC50/EC50 ratio) >20000. Derivative 16, 
showed the highest SI value (SI >282218) within the series; it was superior to NVP, EVF and AZT and 
comparable the reference IASs 1-3. As expected for NNRTI,14 compounds did not show inhibitory 
activity for HIV-2. 
We initially synthesized the 4-pyridinyl derivative 4 by expelling the methylene spacer group. 
Compound 4 proved to be a potent inhibitor of the HIV-1 NL4-3 WT and K103N mutant strains (EC50 
= 0.23 nM), but it was weakly effective against the K103N-Y181C double mutant strain (Table 2). 
Extrusion of the nitrogen atom from the pyridinyl ring of 4 resulted in an equipotent inhibitor of the 
NL4-3 strain; compound 5 showed an interesting inhibition of the K103N-Y181C double mutant strain 
at EC50 = 2137 nM. Furthermore, we introduced two nitrogen atoms at the positions 2 and 4 of the 
benzyl group of 1 to obtain 6. This new IAS derivative potently inhibited the NL4-3 WT strain (EC50 = 
0.22 nM), K103N, Y181C and Y188L mutant strains (EC50 (nM) = 0.22, 0.22, 2.20 and 20.6, 
respectively). Most importantly, 6 proved to inhibit the K103N-Y181C double mutant strain with EC50 
= 132 nM, being >28- and >2.5-fold more potent than NVP and EFV, respectively, and 16-fold 
superior to IAS 1. Shifting the substituents of the 3-phenylsulfonyl moiety from 3’,5’ to 2’,6’ positions 
retained the antiretroviral activity only in the case of the 2’,6’-dichloro derivatives 8 and 10 (compare 
with 7 and 9). 
The replacement of the phenyl group of 3 with a pyridinyl ring to obtain 11 resulted in a general 
improvement of the antiviral activity. Racemate 11 were found to be 3-fold more potent than 3 as 
inhibitor of the NL4-3 WT strain (EC50 = 0.2 nM). Against the Y181C, L100I and K103N-Y181C 
mutant strains IAS 11 was respectively 8- and 6- and 3-times superior to 3. Such results prompted the 
separation at semi-preparative level of the racemic mixture 11 into the pure enantiomers (S)-11 and 
(R)-11 by chiral HPLC (Table 3). The enantiomers proved to be equipotent (EC50 = 0.2 nM) against the 
NL4-3 WT strain, and showed quite similar cytotoxic concentrations (data not shown). On the contrary, 
(S)- and (R)-enantiomer showed significant differences as inhibitors of the HIV-1 mutant strains. In 
particular, (R)-11 demonstrated exceptionally antiretroviral potency against the whole viral panel, 
being 22- (WT, EC50 = 0.2 nM), 61- (K103N, EC50 = 2.1 nM), 6- (Y181C, EC50 = 933 nM) and 27-fold 
K103N-Y181C, EC50 = 150 nM), respectively, more potent than (S)-11 in the cellular assay. 
Compound (R)-11 was remarkably superior to the reference drugs NVP and EFV; with respect to AZT, 
(R)-enantiomer was superior against the WT, K103N and Y181C strains, but was 9-fold inferior against 
the K103N-Y181C mutant strain. Shifting the pyridinyl nitrogen atom from position 4 to either position 
3 or 2 caused a marked reduction of the anti-HIV-1 activity against the mutant strains (compare 12 and 
13 with 11).  
Introduction of a furanyl group for the 6-membered heterocycle led to IAS 16 which showed high 
antiretroviral potency against NL4-3 WT strain (EC50 = 0.2 nM), and the K103N (EC50 = 1 nM) and 
Y181C (EC50 = 4 nM) HIV-1 mutant strains, and the highest SI value (SI >282218). Unexpectedly, 
replacement of the furanyl group with a thiophenyl moiety (17 and 19) caused a reduction of the 
antiviral activity against the mutant viruses. 
Finally, compound (S)-11 and (R)-11 were also evaluated against various HIV-1 group M clinical 
isolates in PBMC. Their antiviral activity was potent and consistent and varied only between 0.7-5.2 
nM when evaluated against all different virus isolates (Table 6). Both compounds showed no activity 
against HIV-2 ROD in PBMC (data not shown). 
 
  
Table 1. Anti-HIV-1 Activity New IASs 4-20 and Reference Compounds 1-3a 
 
 
   
 HIV-1 NL4-3c  HIV-1 IIIBe HIV-2 ROD f 
compd R1 R2 CC50b (nM) EC50 ± SD (nM) SId EC50 ± SD (nM) EC50 (nM) 
4 
 
3,5-Me2 20618 ± 1053 0.23g  89643 ndh nd 
5 
 
3,5-Me2 23769 ± 5904 0.22g 108044 17 ± 1 nd 
6 
 
3,5-Me2 >54953 0.22g >249786 nd nd 
7 H 2,6-Me2 >48924 44.1 ± 16.6 >1109 nd nd 
8 H 2,6-Cl2 16017 ± 13080 0.25g 64068 nd nd 
9 
 
2,6-Me2 >55073 330.4 ± 438 >167 nd nd 
10 
 
2,6-Cl2 >50256 0.81 ± 0.2 >62378 nd nd 
11i 
 
3,5-Me2 30216 ± 2308 0.2 ± 0.2 151078 4.1 ± 1.3 >10000 
12 i 
 
3,5-Me2 54589 ± 3654 0.6g 90981 3.2 ± 1.3 >10000 
13i 
 
3,5-Me2 54589 0.6g 90981 6.6 ± 0.14 >10000 
14 
 
3,5-Me2 30312 ± 1055 41.7 ± 13.1 727 730 ± 170 ≥50000 
15 
 
3,5-Me2 44105 ± 6582 2.1 ± 2.1 21002 nd nd 
16 
 
3,5-Me2 >56433 0.2 ± 0.1 >282218 nd nd 
17 
 
3,5-Me2 >54468 0.7g >77812 5.2 ± 0.2 >10000g 
18 
 
3,5-Me2 32346 ± 17082 0.2g 161730 nd nd 
19 
 
3,5-Me2 >52853 0.84 ± 0.2 >62920 3.4 ± 1.4 >50000 
20 
 
3,5-Me2 25350 ± 1512 0.62g 40887 4.1 ± 1.2 >10000 
1 
 
3,5-Me2 37994 ± 12164 0.22g  172700 5.7 ± 2.1 >10000g 
2 
 
3,5-Me2 37884 ± 15542 2.1 ± 0.9 18040 5.7 ± 1.2 >50000 
3 
 
3,5-Me2 >53535 0.6g >205903 16 ± 12 >10000 
NVP — — >18776 112.4 ± 74.9 >167 19.2 ± 0.0  >10000 
EFV — — >15839 15.9 ± 12.7 >996 1.5 ± 0.3 >10000 
AZT — — >30595 3.7 ± 3.7 >8269 Nd nd 
aData are mean values of two to three independent experiments each one in triplicate.bCC50: cytotoxic concentration (nM) to induce 
50% death of noninfected cells, as evaluated with the MTT method in MT-4 cells. cEC50 (HIV-1 NL4−3)μ effective concentration 
(nM) to inhibit by 50% HIV-1 (NL4−3 strain) induced cell death, as evaluated with the MTT method in MT-4 cells. dSI: selectivity 
index calculated as CC50/EC50 ratio. eEC50 (HIV-1 IIIB): effective concentration (nM) or concentration required to protect CEM 
cells against the cytopathicity of HIV-1 (IIIB strain) by 50%, as monitored by giant cell formation. fEC50 (HIV-2 ROD): effective 
concentration (nM) or concentration required to protect CEM cells against the cytopathicity of HIV-2 (ROD strain) by 50%, as 
monitored by giant cell formation. gLowest detectable nM concentration. hnd: no data. iData of R,S racemic mixture.  
 
 
  
 Table 2. Anti-HIV-1 Activity of Compounds 4-20 against Mutant HIV-1 Strains.a,b 
 EC50 (nM) / FCc 
compd K103N Y181C Y188L L100I K103N-Y181C 
4 0.23
d 
1 
16 ± 21 
70 
1273 ± 489 
5535 nd
e
 >20618 
5 4.4 ± 3.5 20 
66 ± 66 
300 
947 ± 213 
4305 
57 ± 45 
259 
2137 ± 375 
9714 
6 0.22
d
 
1 
2.20 ± 1.3 
10 
50.6 ± 21.9 
257 nd 
132 ± 153 
600 
7 >49389 1120 
42719 ± 4493 
969 
>48924 
1110 nd 
>48924 
1110 
8 >16018 
>64072 
5174 ± 1214 
20696 
>16018 
>64072 nd 
16018 ± 13080 
64072 
9 >55073 
>167 
>55073 
>167 
>55073 
>167 nd 
>55073 
>167 
10 5255 ± 3921 6488 
2526 ± 2082 
3119 
>50527 
>62379 nd 
>50527 
>62379 
11f 9.4 ± 2.3 47 
87 ± 75 
435 nd 
4.7 ± 3.6 
24 
1111 ± 940* 
5555 
12 f 34 ± 13 57 
230 ± 64 
383 nd 
45 ± 50 
75 
6005 ± 256 
10008 
13f 34 ± 7.1 57 
220 ± 49 
367 nd 
20 ± 12 
33 
8483 ± 3633 
14138 
14 16000 ± 7800 384 
>20000 
>480 nd nd 
54953 ± 1055 
1321 
15 64.1 ± 42.7 31 
1474 ± 940 
702 
>42738 
>20351 nd  
>42738 
>20351 
16 0.2
d
 
1 
0.8 ± 0.2 
4 
45 ± 0.23 
225 nd 
971 ± 474 
4855 
17 9.1 ± 2.7 13 
160 ± 180 
229 nd 
7.1 ± 0.85 
10 
>54468 
>77811 
18 2.1 ± 1.5 11 
68 ± 53 
340 
347 ± 217 
1735 nd 
2643 ± 951 
13215 
19 21 ± 20
  
25 
160 ± 110 
190 nd 
5.4 ± 1.6 
6.4 
>52853 
>62920 
20 140 ± 71 226 
670 ± 71 
1081 nd 
140 ± 14 
226 
>48452 
>78148 
1 0.9 ± 0.4 4 
18 ± 7.0 
80 
90 ± 83 
409 nd 
1921 ± 2050 
8691 
2 21 ± 36 10 
107 ± 107 
51 
>36404 
>17335 
19 ± 1 
9 
>53535 
>25493 
3 33 ± 6.4 55 
720 ± 690 
1200 nd 
26 ± 24 
43 
 3267 ± SD 
5445 
NVP >3756 
>33 
>3756 
>33 
>3756 
>33 
60 ± 4 
1.8 
>3756 
>33 
EFV 130 ± 180 8.2 
160 ± 180 
10 
760 ± 630 
48 
22 ± 14 
1.4 
>317 
>20 
AZT 16 ± 12 4.3 
6.0 ± 3.4 
1.6 
33 ± 18 
8.9 nd 
16 ± 13 
1.0 
aData are mean values of two to three independent experiments each one in triplicate. bEC50: effective 
concentration (nM) to inhibit by 50% cell death induced by the indicated mutant HIV-1 strain, as evaluated 
with the MTT method in MT-4 cells. cFC: fold change obtained as ratio between EC50s of the indicated 
drug resistant mutant HIV-1 strain and HIV-1 WT NL4-3 strain. dLowest detectable nM concentration. end: 
no data. fData of R,S racemic mixture. 
 
 
 
  
Table 3. Anti-HIV-1 Activity of Racemate 11 and the Enantiomers (S)-11 and (R)-11 against 
Mutant HIV-1 Strains.a,b 
 EC50 ± SD (nM)  
compd WT K103N Y181C Y188L K103N-Y181C 
11 c 
(R,S) 0.2
d
 9.4 ± 2.3 87 ± 75 ndfd 1111 ± 453 
11 
(S) 0.2
d
 4.3 ± 1.7 128 ± 11 5169 ± 3160 4124 ± 913 
11 
(R) 0.2
d
 0.2d 2.1 ± 1.5 933 ± 38 150 ± 17 
3 c,f 
(R,S) 0.6
d
 33 ± 6.4 720 ± 690 ndd 26 ± 24 
3 f 
(R) 2.1 ± 1.9 4.3 ± 3.2 86 ± 43 193 ± 64 nd 
3 f 
(S) 6.3 ± 4.2 128 ± 107 3469 ± 1735 >36404 nd 
aData are mean values of two to three independent experiments each one in triplicate. bEC50: effective 
concentration (nM) to inhibit by 50% cell death induced by the indicated mutant HIV-1 strain, as 
evaluated with the MTT method in MT-4 cells.  cData of R,S racemic mixture. dLowest detectable nM 
concentration. dnd: no data.  fLit.12 
 
 
 
 
 
  
Table 4. Anti-HIV-1 Activity of Compounds 5, 6 and 11-20 against the WT RT and Mutant RTs 
Carrying Single Amino Acid Substitutionsa 
 IC50 (nM)b 
compd WT K103N Y181I L100I 
5 19 310 226 ndc 
6 42 96 4.2 nd 
11d 40 220 3550 30 
12d 64 100 11100 30 
13d 100 120 >20000 20 
14 >20000 >20000 >20000 9400 
15 16 234 >20000 nd 
16 3 9 234 nd 
17 30 >20000 >20000 100 
18 27 79 nd nd 
19 70 42 >20000 1 
20 44 640 131 160 
1 21 >20000 >20000 15 
2 77 10390 >20000 27 
3 40 540 8228c 70 
NVP 400 7000 >20000 9000 
EFV 80 >20000 400 nd 
ETV 10 20 164 12 
aData represent mean values of at least three separate experiments. bCompound concentration (IC50, 
nM) required to inhibit by 50% the RT activity of the indicated strain. cnd, no data. dData of R,S  
racemic mixture. 
 
 Table 5. Anti-HIV-1 Activity of Racemate 11 and its Enantiomers (S)-11 and (R)-11 against the 
WT RT and Mutant RTs Carrying Single Amino Acid Substitutionsa 
 
 
IC50 (nM)b 
compd WT K103N Y181I/Y181Cc L100I V106A 
11d 
(R,S) 40 220 3500 30 40 
11 
(S) 40 700 110000 20 55 
11 
(R) 18 50 2230 3 26 
3d,e 
(R,S) 40 540 8228
c
 70 50 
3e 
(R) 39 90 2531
c
 50 65 
3e 
(S) 50 9400 >20000
c
 80 28 
NVP  400 7000 >20000  9000 nd 
EFV  80 >20000 400 120 nd 
ETV  10 20 164 12 10 
aData represent mean values of at least three separate experiments. bCompound concentration (IC50, nM) 
required to inhibit by 50% the RT activity of the indicated strain. cThe recombinant HIV-1 RT carrying 
the Y181I mutation was comparable to the Y181C substitution in terms of drug resistance, from an 
enzymological point of view.15 dData of R,S racemic mixture. eLit.12 
 
 
  
Table 6. Inhibitory Activity of Compound (S)-11 and (R)-11 
against various HIV-1 Clades Evaluated in Peripheral Blood 
Mononuclear Cells (PBMC). 
 EC50a,b (nM) 
HIV-1 Clade compd (S)-11 compd (R)-11 
Clade A (UG273) 5.2 3.4 
Clade B (BaL) 2.0 2.1 
Clade C (DJ259) 1.4 0.7 
Clade D (UG270) 4.3 1.8 
Clade A/E (ID12) 4.1 1.2 
Clade F (BZ162) 4.9 1.6 
Clade G (HH8793) 3.6 1.7 
aCompound concentration required to inhibit HIV-1 p24 Ag 
production by 50% in HIV-1-infected PBMC. Data are the mean of 
2 to 3 independent experiments in 2-3 different PBMC donors. 
bThe clinical HIV-1 isolates were sensitive to maraviroc (CCR5 
antagonist) or AMD3100 (CXCR4 antagonist) in their expected nM 
(1-20 nM) range. 
 
 
  
MOLECULAR MODELING
 
In order to gain further insight on the binding mode of the reported compounds, a series of docking 
experiments was carried out following a previously reported methodology.11a From the docking 
simulations versus the HIV-1 WT RT we observed that the PLANTS proposed binding poses of IASs 
4-20 were consistent with the one previously described for the ATIs family,9-12  and featuring mainly 
by these pharmacophoric interaction: (i) the indole NH established a H-bond with the K101 carbonyl 
oxygen; (ii) the chlorine atom fitted into a hydrophobic cavity surrounded by V106 and L234; (iii) the 
3,5-dimethylphenyl moiety lay in the aromatic cleft formed by the side chain of Y181, Y188 and W229 
residues establishing a network of hydrophobic interactions; (iv) the new heteroaryl moieties formed a 
series of hydrophobic interactions with the side chains of V179 and E138:B. It should be noted that the 
extrusion of the nitrogen atom from the aromatic ring did not affect the binding mode. Interestingly, 
two enantiomers (S)-11 and (R)-11 showed an overlapping pose (Figure 2).  
 
 
 
Figure 2. Binding mode of derivatives 5 (yellow), 16 (cyan), (S)-11 (magenta) and (R)-11 (green) 
into the NNBS of the WT RT. Residue of B chain is reported as white stick. 
 
       
Figure 3. Binding mode of derivatives (S)-11 (magenta) and (R)-11 (green) into the NNBS of the K103N RT. The surfaces 
clearly showed the different shape and the position of the methyl group following the induced fit model. 
 
 
 
The docking experiments were also repeated versus the K103N mutated RT. In this case, we 
observed that the binding mode of the majority of the compounds was not affected by the K103N 
mutation. However, the (S)- and (R)-enantiomers showed some significant differences in their binding 
mode: while the methyl group of the (R)-enantiomer pointed toward the cleft created by the K103N 
mutation, sealing the binding pocket and reducing the solvent-accessible surface, the corresponding 
group of the (S)-enantiomer left the pocket more exposed to the solvent. (Figure 3) It should be noted 
that this observation is in accordance with the proposed mechanism of resistance related with the 
K103N mutation based on a binding kinetic effect.16,17  
 
 
 
To gain more information regarding the binding mode of these compounds, we performed a series of 
molecular dynamic simulations of both the WT and K103N mutated RT, in complex with 35 and 36. In 
agreement with the biological data, the simulations into the WT RT produced very similar results for 
the two enantiomers. Furthermore, both complexes showed a significant stability during the whole 
simulation time. 
In the case of the K103N RT/(S)-11 and K103N RT/(R)-11 complexes, the molecular dynamics 
trajectories analyses also showed that both complexes were stable during the whole simulation time. 
This is in accordance with the kinetic hypothesis of resistance, mentioned above.16,17 Following this 
reasoning, the solvation effect on the protein/ligand complexes should play a major role in the binding 
kinetic of (S)-11 and (R)-11 to K103N RT. Thus, to investigate this point, we calculated the solvent 
accessible surface area (SASA)18 of the binding site for both complexes during the simulations time. 
Interestingly, we observed a significant difference between both enantiomers; SASA of the receptor in 
complex with the (S)-enantiomer was greater than the corresponding one for the (R)-enantiomer, 
reporting values of 235.64 Å2 and 210.20 Å2, respectively (it should be noted that the SASA 
computation was performed on the entire binding site). Furthermore, we also calculated the number of 
water molecules inside the binding site, throughout the molecular dynamic simulation. The (S)-
enantiomer showed a number of water molecules surrounding the methyl cleft, 3.5 times greater than 
the number of solvent molecules observed for the (R)-enantiomer. These results support our rationale 
and could provide a justification to the different biological activity observed with (S)-11 and (R)-11 
(Figure 4). 
 
 Figure 4. Four representative frames of the molecular dynamics 
simulation into the K103N mutated RT of the compound (S)-11. 
The water molecules within 6 Å from the ligand centroid are 
reported as blue balls; the waters beyond the binding site are 
reported as pink balls. 
 
 
The IASs binding was thoroughly studied also in the L100I mutated RTs. This mutation seemed not 
to affect the binding mode of IASs 4-20; the favorable interactions described above for the WT RT 
were still present with the L100I RT. These results are in accordance with the experimental IC50 values 
observed ((R)-11, IC50 WT = 18 NM and IC50 L100I = 3 NM). On the other hand, the docking poses 
observed for the Y181I RT (or Y181C RT) clearly showed the loss of the favorable π-π interaction 
between the 3-(3,5-dimethylphenyl) moiety and the phenyl ring of Tyr181. Also in this case the 
analyzed binding pose was coherent with the biological data reporting a weak enzymatic activity ((R)-
11, IC50 Y181I = 2230 nM). 
ADME Studies. Compound (R)-11 (purity >99%) showed excellent plasma and metabolic 
stability, and did not behave as a prodrug. In the plasma stabiliy assay, (R)-11 did not undergo 
hydrolyses for 24 h by the human plasmatic enzymes (Figure 1S, Supporting Information). The 
structures of the metabolites after metabolic oxidative CYP-dependent metabolism, had MW + 16 of 
the parent compound, in agreement with predictions #1 and #4 hypothesized by the Metasite software 
(Figure 2S, Supporting Information). Compound (R)-11 showed good membrane permeability and low 
water solubility (Table 7). 
 
Table 7. ADME Properties of Compound (R)-11. 
 
 
Compd 
PAMPAa 
Papp  10-6 
(cm/s) 
Membrane 
Retention 
(%) 
Water 
Solubility b 
(LogS) 
Metabolic 
Stabilityc 
(%) 
Major 
Metabolites 
(%) 
(R)-11 12.4 0.0 -6.42 99.0  <0.1 
aPAMPA: parallel artificial membrane permeability assay; bLogS: log mol L-1; c% of unmodified parent drug. 
 
 
 
CONCLUSIONS 
We synthesized new indolylarylsulfone derivatives carrying a heterocyclic tail as potential anti-HIV-
1/AIDS agents, with the compounds having different substituents at the indole-2-carboxamide nitrogen. 
Several new indolylarylsulfone (IASs) inhibited the HIV-1 WT (NL4−3 strain) in MT-4 cells with 
EC50 values in the low nanomolar range of concentration, and several compounds yielded EC50 values 
<1.0 nM and SIs >20000. Seven IASs inhibited the K103N HIV-1 mutant strain in MT-4 cells in the 
nanomolar range, and three of them, 4, 6 and 16, yielded subnanomolar EC50 values of 0.23, 0.22 and 
0.2 nM, respectively. These compounds were also potent inhibitors of the Y181C mutation in MT-4 
cells (16: EC50 = 0.8 nM). The pure enantiomers (S)-11 and (R)-11 obtained from the racemic 11 by 
direct HPLC separation were equipotent (EC50 = 0.2 nM) against the NL4-3 WT strain. Most 
importantly, (R)-11 proved to be exceptionally potent and uniformly superior to (S)-11 against the 
whole viral panel with EC50 values of 0.2 nM (WT), 2.1 nM (K103N), 933 nM (Y181C) and 150 nM 
(K103N-Y181C) in MT-4 cells. In the RT screening assay, compound (R)-11 was remarkably superior 
to the reference drugs NVP and EFV and comparable to ETV against the HIV-1 WT, K103N and 
L100I. 
 The binding poses of 4-20 were consistent with the one previously described for the IAS 
NNRTIs. Docking studies of the enantiomers (S)-11 and (R)-11 into the K103N mutated RT showed 
that while the methyl group of the (R)-enantiomer pointed toward the cleft created by the K103N 
mutation, the corresponding group of the (S)-enantiomer left the cleft more exposed to the solvent. The 
calculation of the solvent accessible surfaces pointed out that in the receptor complexed with the (S)- 
enantiomer this area was larger than with the (R)-enantiomer, accounting for the stronger inhibition of 
(R)-11 over (S)-11 against the HIV-1 K103N RT mutation. 
In summary, efforts devoted to improve NNRTI activity focusing not only potency, but also 
aiming at more optimal resistance profile, resulted in the discovery of new valuable antiretroviral 
agents. Compounds 6 and 16 and the enantiomer (R)-11 represent novel robust lead compounds of the 
IAS class that flags the direction for the development of new promising antiretroviral agents for the 
clinical treatment of HIV-1/AIDS. 
 
EXPERIMENTAL SECTION 
Chemistry. All reagents and solvents were commercially available and used without further 
purification. Organic solutions were dried over anhydrous sodium sulfate. Evaporation of the solvents 
was carried out on a Büchi Rotavapor R-210 equipped with a Büchi V-850 vacuum controller and 
Büchi V-700 (~5 mbar) and V-710 (~2 mbar) vacuum pumps. Column chromatographies were run on 
glass columns packed with alumina (Merck, 70-230 mesh) or silica gel (Macherey-Nagel, 70-230 
mesh) eluting with the indicated solvent. Aluminum oxide thin layer chromatography (TLC) cards from 
Fluka (aluminum oxide precoated aluminum cards with fluorescent indicator visualizable at 254 nm) 
and silica gel TLC cards from Macherey-Nagel (silica gel precoated aluminum cards with fluorescent 
indicator visualizable at 254 nm) were used for TLC. Developed plates were visualized by a 
Spectroline ENF 260C/FE UV apparatus. Melting points (mp) were determined on a SMP1 apparatus 
(Stuart Scientific) and are uncorrected. IR spectra were run on a SpectrumOne FT-ATR 
spectrophotometer (Perkin Elmer). Band position and absorption ranges are given in cm-1. Proton (1H 
NMR) nuclear magnetic resonance spectra were recorded on a 400 MHz FT spectrometer (Bruker) in 
the indicated solvent. Chemical shifts are expressed in δ units (ppm) from tetramethylsilane. Elemental 
analyses of tested compounds were found within 0.4% of the theoretical values. Combustion analysis 
was used as a method of establishing compound purity. Purity of tested compounds was ≥95%. 
General Procedure for the Preparation of Derivatives 4-6 and 9-20. Example: 5-Chloro-3-
((3,5-dimethylphenyl)sulfonyl)-N-(pyridin-4-yl)-1H-indole-2-carboxamide (4). A mixture of 21 (100 
mg, 0.27 mmol), pyridin-4-amine (76 mg, 0.81 mmol), BOP reagent (120 mg, 0.27 mmol), and 
triethylamine (81 mg, 0.11 mL, 0.81 mmol) in anhydrous DMF (5 mL) was stirred at 25 °C for 12 h. 
The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was 
washed with brine, dried and filtered. Removal of the solvent gave a residue that was purified by 
column chromatography (silica gel, ethyl acetate:n-hexane = 2:1 as eluent) to furnish 4 (17 mg, 49 %), 
mp 110 °C dec. (from ethanol). 1H NMR (DMSO-d6)μ δ 2.30 (s, 6H), 7.27 (s, 1H), 7.37 (d, J = 8.2 Hz, 
1H), 7.58 (d, J = 8.9 Hz, 1H), 7.65 (s, 2H), 7.69 (d, J = 4.9 Hz, 2H), 7.93 (s, 1H), 8.55 (d, J = 5.6 Hz, 
2H), 11.28 (s, 1H, disappeared on treatment with D2O), 13.27 ppm (br s, 1H, disappeared on treatment 
with D2O). IRμ Ȟ 1648, 2923, 2959 cm-1. Anal. (C22H18ClN3O3S (439.91)) C, H, Cl, N, S. 
N-(3-Aminophenyl)-5-chloro-3-((3,5-dimethylphenyl)sulfonyl)-1H-indole-2-carboxamide (5). It 
was synthesized as 4 starting from 21 and benzene-1,3-diamine. Yield 52%, mp 218-220 °C (from 
ethanol). 1H NMR (DMSO-d6)μ δ 2.29 (s, 6H), 5.21 (br, 2H, disappeared on treatment with D2O), 6.37 
(d, J = 8.6 Hz, 1H), 6.80 (d, J = 7.6 Hz, 1H), 7.01 (t, J = 7.4 Hz, 1H), 7.09 (s, 1H), 7.25 (s, 1H), 7.35 (d, 
J = 8.5 Hz, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.64 (s, 2H), 7.92 (s, 1H), 10.60 (br s, 1H, disappeared on 
treatment with D2O), 13.15 ppm (br s, 1H, disappeared on treatment with D2O). IRμ Ȟ 1660, 3269 cm-1. 
Anal. (C23H20ClN3O3S (453.95)) C, H, Cl, N, S. 
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(pyrimidin-4-ylmethyl)-1H-indole-2-carboxamide 
(6). It was synthesized as 4 starting from 21 and pyrimidin-4-ylmethanamine. Yield 77%, mp 225-
230 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 2.28 (s, 6H), 4.68 (d, J = 5.5 Hz, 2H), 7.26 (s, 1H), 7.35 
(d, J = 8.7 Hz, 1H), 7.56 (d, J = 8.6 Hz, 1H), 7.67 (s, 3H), 7.94 (s, 1H), 8.81 (d, J = 5.2 Hz, 1H), 9.16 (s, 
1H), 9.67 (br s, 1H, disappeared on treatment with D2O), 13.13 ppm (br s, 1H, disappeared on 
treatment with D2O). IRμ Ȟ 1648, 3220 cm-1. Anal. (C22H19ClN4O3S (454.93)) C, H, Cl, N, S. 
5-Chloro-3-((2,6-dimethylphenyl)sulfonyl)-N-(pyridin-4-ylmethyl)-1H-indole-2-carboxamide 
(9). It was synthesized as 4 starting from 22 and pyridin-4-ylmethanamine. Yield 40%, mp 230-235 °C 
(from ethanol). 1H NMR (DMSO-d6)μ δ 2.44 (s, 6H), 4.38 (d, J = 5.7 Hz, 2H), 7.16 (d, J = 7.6 Hz, 2H), 
7.26 (d, J = 5.2 Hz, 2H), 7.34-7.40 (m, 2H), 7.60 (d, J = 8.6 Hz, 1H), 7.76 (s, 1H), 8.49 (d, J = 5.0 Hz, 
2H), 9.22 (br s, 1H, disappeared on treatment with D2O), 13.02 ppm (br s, 1H, disappeared on 
treatment with D2O). IRμ Ȟ 1638, 3251 cm-1. Anal. (C23H20ClN3O3S (453.94)) C, H, Cl, N, S. 
5-Chloro-3-((2,6-dichlorophenyl)sulfonyl)-N-(pyridin-4-ylmethyl)-1H-indole-2-carboxamide 
(10). It was synthesized as 4 starting from 23 and pyridin-4-ylmethanamine. Yield 39%, mp 210-
214 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 4.48 (d, J = 5.8 Hz, 2H), 7.35-7.37 (m, 3H), 7.54-7.60 
(m, 4H), 7.92 (s, 1H), 8.50 (d, J = 5.6 Hz, 2H), 9.32 (br s, 1H, disappeared on treatment with D2O), 
13.19 ppm (br s, 1H, disappeared on treatment with D2O). IRμ Ȟ 1635, 3269, 3321 cm-1. Anal. 
(C21H14Cl3N3O3S (494.78)) C, H, Cl, N, S. 
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-(pyridin-4-yl)ethyl)-1H-indole-2-carboxamide 
(11). It was synthesized as 4 starting from 21 and 1-(pyridin-4-yl)ethanamine. Yield 71%, mp 213-
216 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 1.51 (d, J = 6.9 Hz, 3H), 2.28 (s, 6H), 5.17-5.20 (m, 
1H), 7.25 (s, 1H), 7.34 (d, J = 8.8 Hz, 1H), 7.48 (d, J = 4.8 Hz, 2H), 7.54 (d, J = 8.7 Hz, 1H), 7.60 (s, 
2H), 7.92 (s, 1H), 8.55 (d, J = 4.8 Hz, 2H), 9.46 (d, J = 6.8 Hz, 1H disappeared on treatment with D2O), 
13.04 ppm (br s, 1H, disappeared on treatment with D2O). IRμ Ȟ 1658, 2923, 3312 cm-1. Anal. 
(C24H22ClN3O3S (467.97)) C, H, Cl, N, S. 
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-(pyridin-2-yl)ethyl)-1H-indole-2-carboxamide 
(12). It was synthesized as 4 starting from 21 and 1-(pyridin-2-yl)ethanamine. Yield 43%, mp 222-
225 °C (from ethanol). 1H NMR (CDCl3)μ δ 1.72 (d, J = 6.4 Hz, 3H), 2.29 (s, 6H), 5.41-5.44 (m, 1H), 
7.15 (s, 1H), 7.21-7.35 (m, 4H), 7.59 (s, 2H), 7.68 (t, J = 7.4 Hz, 1H), 8.30 (s, 1H), 8.68 (d, J = 4.6 Hz, 
1H), 10.28 (d, J = 6.8 Hz, 1H, disappeared on treatment with D2O), 10.64 ppm (br s, 1H, disappeared 
on treatment with D2O). IRμ Ȟ 1647, 3212, 3277 cm-1. Anal. (C24H22ClN3O3S (467.97)) C, H, Cl, N, S. 
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-(pyridin-3-yl)ethyl)-1H-indole-2-carboxamide 
(13). It was synthesized as 4 starting from 21 and 1-(pyridin-3-yl)ethanamine. Yield 40%, mp 280-
284 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 1.54 (d, J = 6.8 Hz, 3H), 2.28 (s, 6H), 5.22-5.27 (m, 
1H), 7.24 (s, 1H), 7.30-7.34 (m, 1H), 7.37-7.41 (m, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.58 (s, 2H), 7.87 (d, 
J = 7.5 Hz, 1H), 7.92 (s, 1H), 8.49 (d, J = 4.3 Hz, 1H), 8.70 (s, 1H), 9.43 (br s, 1H, disappeared on 
treatment with D2O), 13.02 ppm (br s, 1H, disappeared on treatment with D2O). IRμ Ȟ 1655, 2923, cm-1. 
Anal. (C24H22ClN3O3S (467.97)) C, H, Cl, N, S. 
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(N’-(pyridin-4-yl)amino)-1H-indole-2-
carbohydrazide (14). It was synthesized as 4 starting from 21 and 4-hydrazinylpyridine. Yield 47%, mp 
231-234 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 2.31 (s, 6H), 5.59 (br, 2H, disappeared on 
treatment with D2O), 7.25 (s, 1H), 7.29 (d, J = 8.5 Hz, 1H), 7.52 (d, J = 8.4 Hz, 1H), 7.63 (s, 2H), 7.69 
(s, 1H), 7.81-7.89 (m, 2H), 8.62 (d, J = 5.5 Hz, 2H), 12.82 ppm (br s, 1H, disappeared on treatment 
with D2O). IRμ Ȟ 1689, 2923, 3554 cm-1. Anal. (C22H19ClN4O3S (454.93)) C, H, Cl, N, S. 
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-(N’-methylamino-N'-phenyl)-1H-indole-2-
carbohydrazide (15). It was synthesized as 4 starting from 21 and 1-methyl-1-phenylhydrazine. Yield 
71%, mp 200 °C dec. (from ethanol). 1H NMR (DMSO-d6)μ δ 2.30 (s, 6H), 3.26 (s, 3H), 6.82 (t, J = 7.6 
Hz, 1H), 7.04 (d, J = 7.3 Hz, 2H), 7.23-7.28 (m, 3H), 7.36 (d, J = 8.1 Hz, 1H), 7.59 (d, J = 8.5 Hz, 1H), 
7.70 (s, 2H), 7.87 (s, 1H) 10.86 (s, 1H, disappeared on treatment with D2O), 13.21 ppm (br s, 1H, 
disappeared on treatment with D2O). IRμ Ȟ 1641, 3219 cm-1. Anal. (C24H22ClN3O3S (467.97)) C, H, Cl, 
N, S. 
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(furan-2-ylmethyl)-1H-indole-2-carboxamide (16). 
It was synthesized as 4 starting from 21 and furan-2-ylmethanamine. Yield 42%, mp 200 °C dec. (from 
ethanol). 1H NMR (DMSO-d6)μ δ 2.29 (s, 6H), 4.58 (d, J = 5.4 Hz, 2H), 6.45 (s, 2H), 7.25 (s, 1H), 
7.33-7.35 (m, 1H), 7.53 (d, J = 9.0 Hz, 1H), 7.59 (s, 2H), 7.65 (s, 1H), 7.93-7.95 (m, 1H), 9.42 (br s, 
1H, disappeared on treatment with D2O), 13.05 ppm (br s, 1H, disappeared on treatment with D2O)). 
IRμ Ȟ 1637, 3210 cm-1. Anal. (C22H19ClN2O4S (442.92)) C, H, Cl, N, S. 
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(thiophen-2-ylmethyl)-1H-indole-2-carboxamide 
(17). It was synthesized as 4 starting from 21 and thiophen-2-ylmethanamine. Yield 73%, mp 252-
255 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 2.27 (s, 6H), 4.75 (d, J = 5.6 Hz, 2H), 7.00-7.03 (m, 
1H), 7.15-7.16 (m, 1H), 7.25 (s, 1H), 7.33 (d, J = 8.8 Hz, 1H), 7.46 (d, J = 4.9 Hz, 1H), 7.53 (d, J = 
8.5 Hz, 1H), 7.58 (s, 2H), 7.95 (s, 1H) 9.51 (br s, 1H, disappeared on treatment with D2O), 13.07 ppm 
(br s, 1H, disappeared on treatment with D2O)). IRμ Ȟ 1647, 2922, 3231 cm-1. Anal. (C22H19ClN2O3S2 
(458.98)) C, H, Cl, N, S. 
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-(thiophen-2-yl)ethyl)-1H-indole-2-
carboxamide (18). It was synthesized as 4 starting from 21 and 1-(thiophen-2-yl)ethanamine. Yield 
41%, mp 215-217 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 1.62 (d, J = 6.8 Hz, 3H), 2.28 (s, 6H), 
5.44-5.50 (m, 1H), 7.00-7.03 (m, 1H), 7.16-7.17 (m, 1H), 7.26 (s, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.46 (d, 
J = 5.0 Hz, 1H), 7.54 (d, J = 8.6 Hz, 1H), 7.58 (s, 2H), 7.94 (s, 1H) 9.48 (d, J = 7.9 Hz, 1H, 
disappeared on treatment with D2O), 13.03 ppm (br s, 1H, disappeared on treatment with D2O)). IRμ Ȟ 
1644, 3238 cm-1. Anal. (C23H21ClN2O3S2 (473.01)) C, H, Cl, N, S. 
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-(thiophen-2-yl)ethyl)-1H-indole-2-
carboxamide (19). It was synthesized as 4 starting from 21 and 2-(thiophen-2-yl)ethanamine. Yield 
82%, mp 222-224 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 2.31 (s, 6H), 3.09-3.17 (m, 2H), 3.58-
3.68 (m, 2H), 6.96-7.00 (m, 2H), 7.26 (s, 1H), 7.32-7.39 (m, 2H), 7.52-7.57 (m, 1H), 7.62 (s, 2H), 7.93 
(d, J = 3.3 Hz, 1H), 9.17 (br s, 1H, disappeared on treatment with D2O), 13.05 ppm (br s, 1H, 
disappeared on treatment with D2O)). IRμ Ȟ 1652, 2854, 3238 cm-1. Anal. (C23H21ClN2O3S2 (473.01)) C, 
H, Cl, N, S. 
5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-
indole-2-carboxamide (20). It was synthesized as 4 starting from 21 and 2-(2-methyl-5-nitro-1H-
imidazol-1-yl)ethanamine. Yield 78%, mp 232-234 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 2.32 (s, 
6H), 2.49 (s, 3H), 3.74-3.77 (m, 2H), 4.48-4.54 (m, 2H), 7.27 (s, 1H), 7.32-7.38 (m, 1H), 7.52-7.56 (m, 
1H), 7.63 (s, 2H), 7.92 (d, J = 3.0 Hz, 1H), 8.06 (s, 1H), 9.23 (br s, 1H, disappeared on treatment with 
D2O), 12.89 ppm (br s, 1H, disappeared on treatment with D2O)). IRμ Ȟ 1600, 2933 cm-1. Anal. 
(C23H22ClN5O5S (515.97)) C, H, Cl, N, S. 
General Procedure for the Preparation of Derivatives 7 and 8. Example: 5-Chloro-3-((2,6-
dimethylphenyl)sulfonyl)-1H-indole-2-carboxamide (7). 30% Ammonium hydroxide (6.5 mL) was 
added to a suspension of 29 (110 mg, 0.28 mmol) in ethanol (11 mL). The reaction mixture was stirred 
for 30 minutes at 60 °C, then 30% ammonium hydroxide (6.5 mL) was added again and the reaction 
was heated at 60 °C overnight. After cooling, the mixture was diluted with water and extracted with 
ethyl acetate. The organic layer was washed with brine, dried and filtered. Removal of the solvent gave 
a residue that was purified by column chromatography (silica gel, ethyl acetate as eluent) to furnish 7 
(30 mg, 35 %), mp 265-270 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 2.46 (s, 6H), 7.18-7.20 (m, 2H), 
7.32-7.40 (m, 2H), 7.68 (d, J = 8.9 Hz, 1H), 7.69-7.71 (m, 1H), 8.08 (br s, 2H, disappeared on 
treatment with D2O), 12.94 ppm (br s, 1H, disappeared on treatment with D2O). IRμ Ȟ 1648, 3227 cm-1. 
Anal. (C17H15ClN2O3S (362.83)) C, H, Cl, N, S. 
5-Chloro-3-((2,6-dichlorophenyl)sulfonyl)-1H-indole-2-carboxamide (8). It was synthesized as 
7 starting from 30 (yield 32%). Spectral and chemico-physical data were in agreement with those 
previously reported.9b 
General Procedure for the Preparation of Derivatives 25 and 26. Example: 5-Chloro-3-
((2,6-dimethylphenyl)thio)-1H-indole-2-carboxylic acid (25). To a mixture of NaH (60 % in mineral 
oil) (220 mg, 5 mmol) in anhydrous DMF (7 mL) was added 24 (450 mg, 2.3 mmol) and the reaction 
mixture was stirred at 25 °C for 10 minutes. 1,2-Bis-(2,6-dimethylphenyl)disulfide (700 mg, 2.5 mmol) 
was added and the reaction mixture was stirred at 100 °C overnight. The reaction mixture was diluted 
with water, made acid with 6N HCl, and extracted with ethyl acetate. The organic layer was washed 
with brine, dried and filtered. Removal of the solvent gave the crude acid that was used without further 
purification. 
5-Chloro-3-((2,6-dimethylphenyl)thio)-1H-indole-2-carboxylic acid (26). It was synthesized as 
25 starting from 24 and 1,2-bis-(2,6-dichlorophenyl)disulfide. It was used as crude product without 
further purification. 
General Procedure for the Preparation of Derivatives 27 and 28. Example: Ethyl 5-chloro-
3-((2,6-dimethylphenyl)thio)-1H-indole-2-carboxylate (27). Thionyl chloride (1.8 g, 1.07 mL, 15 
mmol) was added dropwise to a mixture of 25 in anhydrous ethanol (16 mL, 280 mmol), and the 
reaction was heated at reflux overnight. After cooling the mixture was diluted with water and extracted 
with ethyl acetate. The organic layer was washed with brine, dried and filtered. Removal of the solvent 
gave a residue that was purified by column chromatography (silica gel, ethyl acetate:n-hexane = 1:3 as 
eluent) to furnish 27 (220 mg, 51 %), mp 180-185 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 1.36 (t, J 
= 5.2 Hz, 3H), 2.32 (s, 6H), 4.36-4.42 (m, 2H), 6.41-6.43 (m, 1H), 7.17-7.20 (m, 3H), 7.25-7.27 (m, 
1H), 7.42-7.46 (m, 1H), 12.17 ppm (br s, 1H, disappeared on treatment with D2O). IRμ Ȟ 1671, 3313 
cm-1. 
Ethyl 5-chloro-3-((2,6-dichlorophenyl)thio)-1H-indole-2-carboxylate (28). It was synthesized as 
27 starting from 26. Yield 62%, mp 208-211 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 1.32 (t, J = 7.1 
Hz, 3H), 4.36-4.39 (m, 2H), 6.89 (s, 1H), 7.25 (d, J = 8.8 Hz, 1H), 7.39-7.48 (m, 2H), 7.55-7.57 (m, 
2H), 12.39 ppm (br s, 1H, disappeared on treatment with D2O). IRμ Ȟ 1671, 3296 cm-1. 
General Procedure for the Preparation of Derivatives 29 and 30. Example: ethyl 5-chloro-3-
((2,6-dimethylphenyl)sulfonyl)-1H-indole-2-carboxylate (29). MCPBA (274 mg, 1.2 mmol) was added 
portionwise to a mixture of 27 (220 mg, 0.61 mmol) in chloroform (20 mL) at 0 °C. The reaction 
mixture was stirred at room temperature for 2 h. Water was added and the mixture was extracted with 
chloroform. The organic layer was washed with brine, dried and filtered. Removal of the solvent gave a 
residue that was purified by column chromatography (silica gel, ethyl acetate:n-hexane = 1:2 as eluent) 
to furnish 29 (180 mg, 75 %), mp 190-192 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 1.10 (t, J = 5.5 
Hz, 3H), 2.43 (s, 6H), 4.11-4.16 (m, 2H), 7.16 (d, J = 6.8 Hz, 2H), 7.36 (t, J = 8.6 Hz, 1H), 7.42-7.46 
(m, 1H), 7.62-7.65 (m, 1H), 8.23-8.25 (m, 1H), 13.26 ppm (br s, 1H, disappeared on treatment with 
D2O). IRμ Ȟ 1727, 3360 cm-1. 
Ethyl 5-chloro-3-((2,6-dichlorophenyl)sulfonyl)-1H-indole-2-carboxylate (30). It was 
synthesized as 29 starting from 28. Yield 67%, mp 270-272 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 
1.12 (t, J = 7.2 Hz, 3H), 4.17-4.22 (m, 2H), 7.44-7.48 (m, 1H), 7.56-7.65 (m, 4H), 8.19-8.21 (m, 1H), 
13.35 ppm (br s, 1H, disappeared on treatment with D2O). IRμ Ȟ 1722, 3266 cm-1. 
General Procedure for the Preparation of Derivatives 22 and 23. Example: 5-chloro-3-
((2,6-dimethylphenyl)sulfonyl)-1H-indole-2-carboxylic acid (23). Lithium hydroxide monohydrate (50 
mg, 1.2 mmol) was added to a solution of 27 (180 mg, 0.4 mmol) in THF (5 mL) and water (5 mL). 
Then the reaction mixture was stirred at room temperature for 48 h. After dilution with water, the 
mixture was treated with 1 N HCl until pH 2 was reached. The acid was extracted with ethyl acetate, 
washed with brine, dried and filtered. Removal of the solvent gave a residue that was purified by 
column chromatography (silica gel, chloroform:ethanol = 7:3 as eluent) to furnish 22 (140 mg, 96 %), 
mp 280-285 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 2.46 (s, 6H), 7.05 (d, J = 7.3 Hz, 2H), 7.23 (t, J 
= 8.6 Hz, 2H), 7.55-7.57 (m, 1H), 8.19 (s, 1H), 12.20 ppm (br s, 1H, disappeared on treatment with 
D2O) IRμ Ȟ 1726, 2924, 3358 cm-1. 
5-Chloro-3-((2,6-dichlorophenyl)sulfonyl)-1H-indole-2-carboxylic acid (23). It was synthesized 
as 22 starting from 30. Yield 85%, mp 199-202 °C (from ethanol). 1H NMR (DMSO-d6)μ δ 7.23 (d, J = 
8.0 Hz, 1H), 7.38-7.46 (m, 3H), 7.55-7.60 (m, 1H), 8.10 (s, 1H), 12.54 ppm (br s, 1H, disappeared on 
treatment with D2O). IRμ Ȟ 1611, 3213 cm-1. 
General Procedure for the Preparation of Derivatives 33 and 34. Example: 1,2-bis(2,6-
dimethylphenyl)disulfide (33). 1,3-Dibromo-5,5-dimethylhydantoin (500 mg, 1.8 mmol) was added to a 
mixture of 2,6-dimehylthiophenol (1.0 g, 7.2 mmol, 0.96 mL) in chloroform (15 mL) at room 
temperature. The reaction mixture stirred at 25 °C for 5 minutes. Saturated solution of potassium 
carbonate was added; the mixture was made acidic to pH 2 with 1 N HCl and extracted with 
chloroform, washed with brine and dried. Removal of the solvent gave a residue that was purified by 
column chromatography (silica gel, petroleum ether:dichloromethane = 7:3 as eluent) to furnish 33 
(620 mg, 99 %), mp 90-94 °C (from ethanol) (Lit.19 99-102°C).  
1,2-Bis(2,6-dichlorophenyl)disulfide (34). It was synthesized as 33 starting from 32. Yield 91%, 
yellow solid, mp 202-205 °C (from ethanol) (Lit.20 196 °C).  
Separation of Racemate 11 into the Enantiomers (S)-11 and (R)-11. HPLC 
enantioseparations were performed by using the stainless-steel Chiralcel OD (250 mm x 4.6 mm i.d. 
and 250 x 10 mm i.d.) (Chiral Technologies Europe, Illkirch, France) columns. All chemicals solvents 
for HPLC were purchased from Aldrich (Italy) and used without further purification. The analytical 
HPLC apparatus consisted of a Perkin-Elmer (Norwalk, CT, USA) 200 lc pump equipped with a 
Rheodyne (Cotati, CA, USA) injector, a 20-L sample loop, a HPLC Dionex CC-100 oven (Sunnyvale, 
CA, USA) and a Jasco (Jasco, Tokyo, Japan) Model CD 2095 Plus UV/CD detector. For 
semipreparative separations a Perkin-Elmer 200 LC pump equipped with a Rheodyne injector, a 1 mL 
sample loop, a Perkin-Elmer LC 101 oven and Waters 484 detector (Waters Corporation, Milford, MA, 
USA) were used. The signal was acquired and processed by Clarity software (DataApex, Prague, The 
Czech Republic). The circular dichroism (CD) spectra were measured by using a Jasco Model J-700 
spectropolarimeter. The optical path and temperature were set at 0.1 mm and 20 °C, respectively. The 
spectra are average computed over three instrumental scans and the intensities are presented in terms of 
ellipticity values (mdeg). 
 
Biological Assays. Inhibition of HIV-induced cytopathicity. Biological activity of the compounds was 
tested in the lymphoid MT-4 cell line (received from the NIH AIDS Reagent Program) against the WT 
HIV-1 NL4-3 strain and the different mutant HIV-1 strains, as described before.21 Briefly, MT-4 cells 
were infected with the appropriate HIV-1 strain (or mock-infected to determine cytotoxicity) in the 
presence of different drug concentrations. At day five post-infection, a tetrazolium-based colorimetric 
method (MTT method) was used to evaluate the number of viable cells. The methodology for the anti-
HIV assays in CEM cells had been described previously.22 Briefly, human CEM cell cultures (~3 x 105 
cells/mL-1) were infected with ~100 CCID50 HIV-1 IIIB or HIV-2 ROD per mL and seeded in 200 µL-
well microtiter plates, containing appropriate dilutions of the test compounds. After 4 days of 
incubation at 37 °C, syncytia cell formation was examined microscopically in the CEM cell cultures. 
 Enzymatic assay procedures. Chemicals. [3H]dTTP (40 Ci/mmol) was from Amersham and 
unlabelled dNTP's from Boehringer. Whatman was the supplier of the GF/C filters. All other reagents 
were of analytical grade and purchased from Merck or Fluka. The homopolymer poly(rA) (Pharmacia) 
was mixed at weight ratios in nucleotides of 10:1, to the oligomer oligo(dT)12-18 (Pharmacia) in 20 mM 
Tris-HCl (pH 8.0), containing 20 mM KCl and 1 mM EDTA, heated at 65 °C for 5 min and then slowly 
cooled at room temperature. The coexpression vectors pUC12N/p66(His)/p51with the wild-type or the 
mutant forms of HIV-1 RT p66 were kindly provided by Dr. S. H. Hughes (NCI-Frederick Cancer 
Research and Development Center). Proteins were expressed in E. coli and purified as described.23 
RNA-dependent DNA polymerase activity was assayed as follows: a final volume of 25 µL contained 
reaction buffer (50 mM Tris-HCl pH 7.5, 1 mM DTT, 0.2 mg/mL BSA, 4% glycerol), 10 mM MgCl2, 
0.5 µg of poly(rA)/oligo(dT)10:1 (0.3 µM 3'-OH ends), 10 µM [3H]-dTTP (1Ci/mmol) and 2-4 nM RT. 
Reactions were incubated at 37 °C for the indicated time. 20 µL-Aliquots were then spotted on glass 
fiber filters GF/C which were immediately immersed in 5% ice-cold TCA. Filters were washed twice in 
5% ice-cold TCA and once in ethanol for 5 min, dried and acid-precipitable radioactivity was 
quantitated by scintillation counting. Reactions were performed under the conditions described for the 
HIV-1 RT RNA-dependent DNA polymerase activity assay. Incorporation of radioactive dTTP into 
poly(rA)/oligo(dT) at different substrate (nucleic acid or dTTP) concentrations was monitored in the 
presence of increasing fixed amounts of inhibitor. Data were then plotted according to Lineweaver-
Burke and Dixon. For Ki determination, an interval of inhibitor concentrations between 0.2 Ki and 5 Ki 
was used. 
 Inhibition of HIV-1 clades. Inhibition of various HIV-1 clades (group M) was evaluated in 
PBMC. PBMCs from healthy donors were stimulated with PHA at 2 µg/mL (Sigma, Bornem, Belgium) 
for 3 days at 37 °C. The PHA-stimulated blasts were then seeded at 0.5 x 106 cells per well into a 48-
well plate containing varying concentrations of compound in cell culture medium (RPMI 1640) 
containing 10% FCS and IL-2 (25 U/mL, R&D Systems Europe, Abingdon, UK). The virus 
stocks were added at a final dose of 250 pg p24 or p27/mL. The primary clinical isolates representing 
different HIV-1 clades of group M and an HIV-2 isolate were all kindly provided by Dr. J. Lathey then 
at BBI Biotech Research Laboratories, Inc., Gaithersburg, MD, and their co-receptor use (R5 or X4) 
was determined in our laboratory in U87.CD4.CXCR4 and U87.CD4.CCR5 cells. Cell supernatant 
was collected at day 10-12 after infection and HIV-1 core Ag in the culture supernatant was analyzed 
by a p24 Ag ELISA kit (Perkin Elmer, Zaventem, Belgium). For HIV-2 p27 Ag detection the 
INNOTEST from Innogenetics (Temse, Belgium) was used.24 
  
Molecular Modeling. All molecular modeling studies were performed on a Intel® Xeon(R) CPU 
E5462 2.80 GHz x 4 running Ubuntu 12.04 LTS. The RT structures were downloaded from the PDB 
(WT RTs: 2rf215, K103N RT: 1fk0,25 L100I RT: 1S1T RT,26 the Y181I mutation was obtained by 
mutating the specific residue in the 1jkh27 crystal using the rotamer explorer tool in MOE and using the 
lowest energy conformation obtained. Hydrogen atoms were added to the protein using Molecular 
Operating Environment (MOE) 2010.1028 and minimized, keeping all the heavy atoms fixed until a 
rmsd gradient of 0.05 kcal mol-1 Å-1 was reached. Ligand structures were built with MOE and 
minimized using the MMFF94x force field until a rmsd gradient of 0.05 kcal mol-1 Å-1 was reached. 
The docking simulations were performed using PLANTS 1.1.29 We set the binding lattice as a sphere 
of 10 Å binding site radius from the center of WT and mutated RT co-crystallized inhibitor. All 
Molecular Dynamics (MD) simulations were performed on Desmond package of Maestro 
SCHRÖDINGER 2.4,30,31 using OPLS all-atom force field 2005.32,33 All protein complex system for 
MD simulations were prepared by Desmond set up wizard. The complexes were solvated in a periodic 
octahedron simulation box using TIP3P water molecules, providing a minimum of 10 Å of water 
between the protein surface and any periodic box edge. Chlorine ions were added to neutralize the 
charge of the total system. 
The systems were equilibrated with the default protocol provided in Desmond. Two rounds of 
steepest descent were performed with a maximum of 2000 steps on a restraint of 50 kcal/mol per Å2. 
Then, a serie of four molecular dynamic equilibrations were performed. The first simulation was run 
for 12 ps at a temperature of 10 °K in the NVT ensemble with proteins and ligands heavy atoms 
restrained with force constant of 50 kcal/mol per Å2. Another 12 ps simulation was performed with the 
same harmonic restraints; this time in the NPT ensemble. A 24-ps simulation followed with the 
temperature raised to performed at 300 °K in the NPT ensemble and the force constant retained. 
Finally, a 24-ps simulation was performed at 300 °K in the NPT ensemble with all restraints removed. 
Following minimization, the entire system was heated to 300 °K with constant pressure of 1.013 bar 
and periodic boundary condition for 20 ns. Trajectories analysis were carried out by Simulation 
Integrations Diagram of Desmond application. SASA was computed every ten frames in each step and 
the binding cavity of the protein was defined by a 5 Å radius from the bound ligand, using a python 
script developed by Schrödinger. The computation of the water molecules inside the binding site was 
determined by counting the water molecules within a specified distance of 6 Å from the ligand 
centroid. The images in the manuscript were created with MOE 2010.10 and Maestro SCHRÖDINGER 
2.4. 
 
Purity determination. Compound  (R)-11 was dissolved in DMSO (1 mM) and analysed by LC-
UV-MS chromatography. LC analysis were performed with an Agilent 1100 LC/MSD VL system 
(G1946C) (Agilent Technologies, Palo Alto, CA) equipped with vacuum solvent degassing unit, binary 
high-pressure gradient pump, 1100 series UV detector, and 1100 MSD model VL bench top mass 
spectrometer. Chromatographic profiles were obtained using a Kinetex  C18 column (Phenomenex,  
100 x 4.6 mm, 2.6 ȝm particle size, and gradient elution: eluent A = ACN, eluent B = water. The 
analysis started with 2% of A, which rapidly increased up to 70% in 12 min and then slowly up to 98% 
in 20 min. The flow rate was 0.4 mL min-1 and injection volume was 20 ȝL.  
The Agilent 1100 series mass spectra detection (MSD) single-quadrupole instrument carried an 
orthogonal spray API-ES (Agilent Technologies, Palo Alto, CA). Nitrogen was used as nebulizing and 
drying gas. The pressure of the nebulizing gas, flow of the drying gas, capillary voltage, fragmentor 
voltage, and vaporization temperature were set at 40 psi, 9 L/min, 3000 V, 70 V, and 350 °C, 
respectively. UV detection was monitored at 254 nm. The LC-ESI-MS determination was performed 
by operating the MSD in the positive ion mode. Spectra were acquired over the scan range m/z 100-
1500 using a step size of 0.1 . The compound purity was determined by measuring the peak areas 
detected at 254 nm. 
Water Solubility Assay.  Compound (R)-11 (1 mg) was added as a powder to 1 mL of water. 
The mixture was stirred at room temperature for 24 h. The suspension was taken off by a 0.45 ȝm 
nylon filter (Acrodisc), and the solubilized compound was determined by LC-UV-MS assay. The 
experiments were carried out in triplicate. The quantification was performed with ES interface and 
Varian MS Workstation System Control Vers. 6.9 software. Chromatographic analysis was carried out 
as above reported; gradient elution: eluent A = ACN, eluent B = water containing 0.1% formic acid. 
The analysis started with 0% of A, which linearly increased up to 70% in 10 min and then slowly up to 
98% in 15 min. The flow rate was 0.2 mL min-1 and injection volume was 5 ȝL. The instrument 
operated in positive mode with detector 1850 V, drying gas pressure 25.0 psi, desolvation temperature 
300 °C, nebulizing gas 40 psi, needle 5000 V and shield 600 V. Nitrogen was used as nebulizer gas  
and drying gas. Collision induced dissociation was performed using Argon as the collision gas at a 
pressure of 1.8 mTorr in the collision cell. The transitions as well as the capillary voltage and the 
collision energy used for compound are summarized in Table 8.  
 
  Table 8.  Chromatographic and MS Parameters of Compound (R)-11. 
 
Compd 
Transitiona 
(m/z) 
Collision 
Energy 
(eV) 
Capillary 
Voltage 
(V) 
tRb 
(min) 
(R)-11 348.8 105.8 
-24.0 
-22.5 18 99.0 
amonitored transition; bretention time.
 
 
 
Parallel Artificial Membrane Permeability Assay (PAMPA). Donor solution of compound 
(R)-11 (0.5 mM) was prepared by diluting 1 mM DMSO stock solution with phosphate buffer (pH 7.4, 
intestinal permeability. The donor solution (150 ȝL) was added to each well of the filter plate. To each 
well of the acceptor plate were added 300 ȝL of 50% DMSO - phosphate buffer solution. The 
experiments were carried out in three plates on different days. The sandwich was incubated for 5 h at 
room temperature under gentle shaking. After incubation, the plates were separated, and samples were 
taken from both receiver and donor sides and analysed using LC with UV detection at 254 nm. LC 
analysis were performed with a Perkin-Elmer series 200 provided with an UV detector (Perkin-Elmer 
785A, UV/vis Detector). Chromatographic separations were achieved using a Kinetix C18 column 
(Phenomenex,  100 x 4.6 mm, 2.6 ȝm particle size at a flow rate of 0.6 mL min-1 and a mobile phase of 
6:4 ACN-water. 
Permeability (Papp) for PAMPA was calculated according to the following equation, obtained 
from Wohnsland and Faller,34 and Sugano et al.35 and modified in order to obtain permeability values 
in cm/s, 
   rAtVV VVP AD ADapp  1ln
 
where VA is the volume in the acceptor well, VD is the volume in the donor well (cm3), A is the effective 
area of the membrane (cm2), t is the incubation time (s) and r the ratio between drug concentration in 
the acceptor and equilibrium concentration of the drug in the total volume (VD+VA). Drug concentration 
is estimated by using the peak area integration. 
 Membrane retention (%) was calculated according to the following equation:  
Eq
ADrMR 100)]([% 
 
where r is  the ratio between drug concentration in the acceptor and equilibrium concentration, D, A, 
and Eq represent drug concentration in the donor, acceptor and equilibrium solution, respectively.
 
 
Microsomal Stability Assay. Compound (R)-11 in DMSO solution was incubated at 37 °C for 
60 min in 25 mM phosphate buffer (pH 7.4), 5 ȝL of human liver microsomal protein (0.2 mg/mL), in 
the presence of a NADPH-generating system at a final volume of 0.5 mL and concentration of 50 ȝMν 
DMSO did not exceed 2%. The reaction was cooled on ice and quenched by adding 1.0 mL of ACN. 
The reaction mixtures were centrifuged for 15 min at 10000 rpm, and the parent drug and its 
metabolites were determined by LC-UV-MS. The chromatographic analysis was performed as above 
reported. The percentage of unmetabolized compound was calculated using reference solutions. The 
experiments were performed in triplicate and the metabolic behaviour was predicted by means of 
Metasite software. 
 Plasma Stability Assay. To determine the enzymatic stability, pooled human plasma (750 µL), 
phosphate buffer (pH 7.4, 700 µL), and 50 µL of 3.0 mM solution of (R)-11 in DMSO (final 
concentration 100 µM) were mixed in a test tube. The mixture was incubated at 37 °C. At the time 
points of 0 h and 24 h aliquots of a 150 µL were removed, mixed with 600 µL of cold ACN and 
centrifuged at 5000 rpm for 15 min. The supernatant was removed and analysed by HPLC. The 
stability was checked by HPLC with UV-MS detector as above reported. 
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